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Abstract: Vibrational spectroscopy analyses vibrations within a molecule and can be
used to characterise a molecular structure. Raman spectroscopy is one of the vibrational
spectroscopic techniques, in which incident radiation is used to induce vibrations in the
molecules of a sample, and the scattered radiation may be used to characterise the sample
in a rapid and non-destructive manner. Infrared (IR) spectroscopy is a complementary
vibrational spectroscopic technique based on the absorption of IR radiation by the sample.
Molecules absorb specific frequencies of the incident light which are characteristic of their
structure. IR and Raman spectroscopy are sensitive to subtle biochemical changes occurring
at the molecular level allowing spectral variations corresponding to disease onset to be
detected. Over the past 15 years, there have been numerous reports demonstrating the
potential of IR and Raman spectroscopy together with multivariate statistical analysis
techniques for the detection of a variety of cancers including, breast, lung, brain, colon,
oral, oesophageal, prostate and cervical cancer. This paper discusses the recent advances
and the future perspectives in relation to cancer screening applications, focussing on cervical
and oral cancer.
Keywords: optical diagnosis; lasers; Raman spectroscopy; FTIR spectroscopy;
cervical cancer; oral cancer; screening; cytology
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1. Introduction
Cancer is a leading cause of disease worldwide with 14.1 million new cases, 8.2 million cancer
deaths and 32.6 million people living with cancer (within five years of diagnosis) in 2012 [1].
Many cancers develop through pre-malignant stages which allow screening programmes to be
implemented to detect cellular changes before invasive cancer develops. A good example is cervical
cancer screening using the Papanicolaou (Pap) test which involves microscopic examination of cells
exfoliated from the cervix.
Cytology is the study of disease at the cellular level and involves the preservation, staining and
microscopic examination of cells that have been extracted from the body. Cytology can be used for
practically any tissue type to detect abnormal cells. The principle of cytology is based on the fact that
cancer cells lose their adhesive properties early in the disease process and can thus be easily exfoliated
from tissue. An advantage of cytology is that sample collection is generally simple, rapid and painless.
Cytological screening aims to detect pre-cancer and cancer in a healthy population. In such
populations, disease prevalence is relatively low and achieving a high test sensitivity is critical
(see Figure 1). The aim of screening is to correctly identify as many cases of disease (positives)
as possible while minimising incorrect identification of disease in individuals who do not have the
disease (false positives) and negatives in individuals who do have the disease (false negatives). A false
positive would result in a patient possibly undergoing unnecessary treatment while a false negative
would result in a patient remaining undiagnosed and possibly progressing to cancer.
There is an unmet clinical need for new methods to aid cytologists in the early detection of
pre-cancer. These methods ideally should be rapid, non-destructive, require minimal sample preparation
and mostly importantly should not be subjective.

Sensitivity

Specificity

• a measure of the ability of the
screening test to identify
positives
• expressed as the percentage of
positives correctly identified
by the test out of the total
number of positives actually
tested

• a measure of the ability of the
screening test to identify
negatives
• expressed as the percentage of
negatives correctly identified
by the test out of the total
number of negatives actually
tested

Figure 1. Definition of sensitivity and specificity.
2. Vibrational Spectroscopy
Vibrational spectroscopy analyses vibrations within a molecule and the spectrum of vibrational
energies or frequencies (in wavenumbers, cm−1) can be used to characterise a molecular structure.
Every molecule has a unique spectrum which allows identification of the molecular compound and its
abundance in a sample [2].
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The exact energy required to excite a molecular vibration depends on the masses of the atoms
involved in the vibration and the type of chemical bonds between these atoms and may be influenced
by molecular structure, molecular interactions and the chemical microenvironment of the molecule.
Vibrational energies fall within the mid Infrared (IR) region of the electromagnetic spectrum and
are commonly probed using IR absorption spectroscopy. IR spectroscopy is based on the absorption of
infrared radiation by the sample and the fact that molecules absorb specific frequencies of the incident
light which are characteristic of their structure.
A typical cellular FTIR spectrum is shown in Figure 2, together with a list of tentative spectral
assignments in Table 1 [3]. The spectrum shown in Figure 2 can be divided into two regions, the high
wavenumber region from 2500–4000 cm−1, corresponding to absorptions due to O-H, N-H, C-H
stretching vibrations, and the fingerprint region from 900–1800 cm−1, which consists of many
overlapping bands (see Table 1), and is characteristic of the sample.

Figure 2. Typical FTIR spectrum from a population of cells.
Table 1. Tentative peak assignments [3] for typical FTIR cellular spectrum shown in Figure 2.
Wavenumber (cm−1)
1036
1080
1150
1220–1280
1310
1450–1470
1520–1550
1620–1700
2850
2920
2960
3290
3400

FTIR Peak Assignments
C-C skeletal stretching (proteins)
PO2 symmetric stretching (DNA/RNA)
C-C and C-O stretching (proteins)
PO2 asymmetric stretching (DNA/RNA), Amide III (C-N stretching, N-H bending, proteins)
CH2 stretching (phospholipids)
CH3 asymmetric stretching (proteins, lipids)
Amide II (N-H bending, C-N stretching, proteins)
Amide I (C=O stretching, C-N stretching and N-H bending, proteins)
CH2 symmetric stretching (lipids)
CH2 asymmetric stretching (lipids)
CH3 asymmetric stretching (lipids and proteins)
NH asymmetric stretching (proteins)
OH stretching (water)
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Raman spectroscopy is an optical method based on inelastic light scattering. The sample is illuminated
by monochromatic laser light and interactions between the incident photons and molecules in the
sample result in scattering of the light. The coupling of the light generates vibrations within the
material, which are again characteristic of the chemical structure, and the energy of the scattered light
is reduced by an amount equal to the energy of the vibrational energy. Thus, the positions, relative
intensities and shapes of the bands in a Raman spectrum carry detailed information about the molecular
composition of the sample.
A typical cellular Raman spectrum is shown in Figure 3, together with a list of tentative spectral
assignments in Table 2 [4]. As for Figure 2, the spectrum can be divided into two regions, the high
wavenumber region, from 2500–3500 cm−1, and the fingerprint region, from 400–1800 cm−1.

Figure 3. Typical cellular Raman spectrum.
Table 2. Tentative peak assignments [4] for typical Raman cellular spectrum shown in Figure 3.
Wavenumber (cm−1)
621
642
670
720
750
782
827
854
935
1003
1030
1080
1085

Raman Peak Assignments
C-C twisting mode of Phenylalanine (proteins)
C-C twisting mode of Tyrosine and Phenylalanine
Thymine, Guanine (DNA/RNA)
C-N stretching in Adenine and lipids
symmetric breathing of Tryptophan (protein)
Uracil, Thymine, Cytosine (ring breathing modes in the DNA/RNA)
PO2 stretching in DNA, Tyrosine
Ring breathing in Tyrosine and Proline (proteins)
C-C stretching mode of Proline and Valine
C-C aromatic ring stretching in Phenylalanine
C-H bending mode in Phenylalanine, C-N stretching in proteins
PO2 symmetric stretching (DNA/RNA)
C-O stretching
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Table 2. Cont.

Wavenumber (cm−1)
Raman Peak Assignments
1130
C-N stretching in proteins; C-O stretching in carbohydrates
1155
C-C and C-N stretching of proteins/lipids
1175
C-H in plane bending mode of Tyrosine and Phenylalanine; Cytosine, Guanine
1208
C-C6H5 stretching mode in Tryptophan, Phenylalanine
1220–1280
Amide III (C-N stretching, N-H bending, proteins), PO2 asymmetric stretching (DNA/RNA)
1311
CH3/CH2 twisting mode of collagen and lipid
1340
Guanine (DNA/RNA), CH def. in proteins and carbohydrates
1430–1460
CH (CH2) bending mode in proteins and lipids
1485
Amide II (N-H bending, C-N stretching, proteins); Adenine, Guanine (DNA/RNA)
1580
Adenine, Guanine (DNA/RNA); C=C bending mode of Phenylalanine
1615
C=C Phenylalanine, Tyrosine and Tryptophan
1620–1700
Amide I (C=O stretching, C-N stretching and N-H bending, proteins)
2890
CH2 symmetric stretching (lipids)
2940
CH2 and CH3 symmetric stretching (lipids)
2980
CH3 symmetric stretching (lipids)

Raman and IR spectroscopy are complementary techniques. IR spectroscopy involves the absorption
of radiation whereas Raman spectroscopy is a scattering technique, whereby the incident radiation
couples with the vibrating polarisation of the molecule and generates or annihilates a vibration. These
different underlying mechanisms give rise to the complementarity of the two techniques and they each
have different selection rules. For a vibration to be active in IR spectroscopy, a change in dipole is
required, whereas a change in polarisability is required for a vibration to be Raman active. Vibrations
of asymmetric, polar bonds tend to be strong in IR spectra, whereas symmetric, nonpolar groups are
strong in Raman spectra. For example, O-H vibrations of water are very strong in IR spectra, whereas
they are relatively weak in Raman spectra. This feature means that Raman spectroscopy may be a more
suitable technique for biological applications. Another difference is that Raman spectroscopy can be
employed in the UV, visible or near IR regions of the electromagnetic spectrum whereas IR spectroscopy
monitors the absorption of IR radiation. Therefore, Raman spectroscopy has a higher spatial resolution
(<1 µm for Raman, ~5–10 µm for IR). Raman spectroscopy is, however, inherently weak with only a small
percentage of photons undergoing Raman scattering (~10−6). Longer spectral acquisition times are
therefore needed to achieve adequate signal to noise in Raman compared to IR spectroscopy.
IR and Raman spectra of biomedical samples such as cells and tissues are a superposition of all the
contributions from each individual biochemical component such as DNA, RNA, proteins, lipids and
carbohydrates. Thus vibrational spectroscopy methods can provide a molecular diagnosis by providing
a “biochemical fingerprint” of the complete genome, proteome and metabolome of the cell or tissue [5].
This can be provided in a rapid, label free, non-destructive manner allowing additional analyses to be
performed subsequently, such as staining, immunocytochemistry etc. Standardised methods and procedures
for collecting IR spectra and images from biological samples have recently been described [6].
In recent years, Raman and FTIR spectroscopy have been used in the detection of a variety of
cancers, including breast, prostate, oesophageal, colon, lung, oral and cervical cancer, and excellent
sensitivity and specificity values have been reported [7–9].
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For the purposes of this review, cervical and oral cancers will be focussed on as these tissues are
readily accessible and amenable to cytological screening.
3. Cervical Cancer
Cervical cancer is the fourth most common cancer in women worldwide with an estimated 528,000
new cases and 266,000 deaths in 2012 [1]. The mortality associated with cervical cancer can be reduced
if this disease is detected at the early stages of development or at the pre-malignant state (cervical
intraepithelial neoplasia, CIN).
Currently, a Papanicolaou test is used to screen for CIN and cervical cancer in the general female
population. The Papanicolaou test (also called Pap smear, Pap test, cervical smear, or smear test) is
a screening test used to detect cancer and pre-cancer in the ectocervix. A spatula or cytobrush is used
to collect the cells from the cervix and after placing in liquid fixative, the cells are then collected on
a filter and transferred to a slide and stained. The cells are examined for abnormalities under the
microscope by highly trained personnel. The Pap test is an effective, widely used method for early
detection of cervical cancer and pre-cancer. Despite a high specificity of 95%–98%, the sensitivity of
the Pap test is reported to vary greatly from 74% to 96% [10]. Low grade dysplasia or CIN 1 can
spontaneously regress without leading to cervical cancer. However some CIN 1 lesions progress to
moderate (CIN 2) and subsequently severe dysplasia (CIN 3), finally progressing to invasive cancer [11].
An abnormal Pap smear is followed by colposcopy, biopsy and histological confirmation of the diagnosis.
This involves the visual examination of histological sections by highly trained personnel. The grading
characteristics are quite subjective and pre-malignancy may not be visually perceptible at all.
Persistent infection with high-risk human papillomavirus (HPV) (e.g., HPV types 16, 18) is accepted
as the major cause for the development of cervical pre-cancer and cancer [12]. HPV testing has
recently been introduced in parallel with Pap smear screening for safe and cost-effective lengthening
of the cervical screening interval due to its high-negative predictive values [13]. The HPV DNA test
identifies high-risk HPV oncogene expression. However, this test is expensive, time-consuming and
requires experienced technicians. Over the last decade, prophylactic HPV vaccines have been developed
but despite the introduction of these vaccines, there is still a need for regular cervical screening, as the
vaccines do not protect against all oncogenic HPV types. Additionally, some women may not benefit
from the vaccines if there is a pre-existing HPV infection or they do not receive the complete number
of doses (three doses over a 6-month period). After vaccination, women must still get routine Pap tests
which can detect abnormal cervical growth regardless of what HPV type causes it to develop.
The first investigations of cervical exfoliated cells using IR spectroscopy were in the early 1990’s
by Wong and co-workers. They published a number of papers showing significant differences between
normal, pre-cancer and cancer samples [14–17].
These initial studies recorded spectra from cell pellets rather than from individual cells and a number
of confounding factors such as polymorphs, endocervical columnar cells, metaplastic cells, cervical
mucus and debris were subsequently identified [18]. Further investigations by other groups identified
similar confounding factors such as inflammation, metaplasia, hormonal changes, metabolic activity,
blood, mucus [19–23].
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However, an important early study by Cohenford and Rigas [24] showed that the FTIR spectra of
morphologically normal exfoliated cells from women with dysplasia or cancer exhibit extensive IR
spectroscopic changes. This finding was later confirmed by Schubert et al. [25] who showed spectral
changes in cytologically normal cells, most likely due to HPV infection.
Walsh et al. [26] employed attenuated total reflection (ATR) FTIR spectroscopy to show spectral
differences between normal and low grade and high grade dysplasia cytology samples. ATR-FTIR
spectroscopy involves the IR beam being directed through a high refractive index crystal, typically
diamond, germanium or zinc, where it undergoes total internal reflection generating an evanescent
waveform that interacts with the biological sample at the surface of the crystal. Interestingly, a recent
ATR—FTIR study has shown that cervical pre-cancer is more accurately identified when histology
rather than cytology is used as the gold standard to classify the samples [27].
ATR-FTIR spectroscopy has also been shown to be capable of distinguishing between high risk
HPV infections in women with low grade and high grade dysplasia [28]. Interestingly, spectral differences
were also found between women in their 20s and in their 30s in samples of the same cytological grade
and HPV type, most likely because of a persistent HPV infection. Schubert et al. [25] also showed that
FTIR spectroscopy could discriminate cervical exfoliated cells based on their HPV status. In addition,
a number of studies have used cervical cell lines as model systems to show the ability of vibrational
spectroscopy (both IR and Raman) to differentiate cells based on HPV status [28–33].
In contrast to the extensive work on exfoliated cervical cells using IR spectroscopy, there are relatively
few studies using Raman spectroscopy, most likely because of the issues with confounding factors.
Vargis et al. [33] showed that Raman spectroscopy could classify HPV-positive and -negative cytology
samples with an accuracy of 98.5%. A study by Rubina et al. [34] used Raman spectroscopy to distinguish
between normal and cervical cancer cytology samples. As the spectra of cervical cancer samples were
dominated by blood features, cytology samples were treated with red blood cell lysis buffer prior to
Raman acquisition. A classification accuracy of ~80% was obtained. Both of these studies used cell
pellets rather than recording Raman spectra from individual cells and this probably resulted in the
relatively low classification accuracy in the study by Rubina et al. due to sample heterogeneity.
A recent study by Bonnier et al. [35] addressed many of the issues involved in recording Raman
spectra from ThinPrep cervical cytology samples. A new method based on pre-treatment of the slides
with hydrogen peroxide to clear blood residue contamination before Raman recording was shown to
minimise variability within the data sets. This resulted in the collection of highly reproducible data
with clear discrimination between negative cytology and CIN cytology. Importantly, all data was recorded
on glass ThinPrep slides which are currently used for clinical cervical cytology rather than spectroscopic
substrates such as MirrIR or calcium fluoride substrates which are commonly used for research purposes
and, although they reduce the presence of confounding contributions of the substrate, are considerably
more expensive.
4. Oral Cancer
Oral cancer is defined as squamous cell carcinoma of the lip, oral cavity and oropharynx, and is the
sixth most common malignancy in the world [36]. Patients with oral squamous cell carcinoma (OSCC)
often have a poor outcome even though advances in treatment have been made. The 5 year survival
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rate is approximately 80% for early stage disease but only approximately 20% for late stage disease [37]
and patients often present with advanced disease. Multiple primary tumours are common and second
primary tumours are the most common cause of death in patients with early stage disease [38].
OSCC is a multi causal disease and risk factors include lifestyle habits (tobacco exposure and alcohol
consumption), dietary factors, occupational activity, socioeconomic status, exposure to external agents,
and genetic susceptibility [39,40]. Most cases of oral cancer occur in patients of 60 years or over and
the risk increases with advancing age.
The gold standard method for diagnosis of oral cancer and pre-malignant lesions is clinical examination
and histopathological evaluation of biopsied tissue [41]. Conventional visual and tactile examination
(CVTE) is used to detect OSCC and pre-malignant oral lesions in a screening setting but oral
pre-malignant lesions and some early OSCC can be difficult to distinguish from inflammatory lesions.
Most lesions are white patches known as leukoplakia and only approx. 4% of these lesions progress to
cancer. CVTE cannot distinguish between these lesions and non-progressive lesions. Biopsy is followed
by histopathology, where the excised tissue is processed, cut into sections and mounted on a glass slide
for examination by a pathologist. Grading of tumours depends on the visual assessment of tissue
architecture and characteristics of individual cells. The grading characteristics used are highly subjective
and early proliferation/pre-malignancy may not be apparent morphologically. In addition, it can be
difficult to discriminate between reactive/inflammatory lesions and pre-cancer lesions.
A number of screening and diagnostic aids for early detection and diagnosis of oral cancer and
pre-cancer have become available over the last decade including brush biopsy, toluidine blue vital
staining, post-acetic acid rinse tissue reflectance and tissue autofluorescence. Some of these techniques
show promise but as yet none has been definitively proven to perform better than conventional visual
examination [42]. Well designed clinical studies are needed where the techniques are directly compared
to the diagnostic gold standard, scalpel biopsy and histopathology.
Early detection of cancer greatly increases the chances for successful treatment. There is a significant
clinical need for new techniques that can detect pre-malignant changes that may progress to cancer. Oral
cancer progression is not as clear cut as, for example, in cervical cancer in which there is a well-defined
progression from mild to moderate to severe dysplasia (CIN 1, 2 and 3). The majority of histologically
pre-malignant oral lesions do not progress to cancer at all and mild dysplasia can progress to cancer as
readily as severe dysplasia. In a long term follow up of 236 patients with oral lesions, Holmstrup et al. [43]
found that the degree of dysplasia was not a predictor of malignant potential of the lesions. The
inability of conventional histopathology to predict which lesions will progress to cancer underlines the
need for new techniques or new technologies to address this clinical need.
While a number of Raman spectroscopy studies have been carried out on oral tissues [44–46],
to date, only a limited number of IR studies have focused on oral exfoliated cells.
Papamarkakis et al. [47] showed that oral cells could be classified according to anatomical region
with cells from cheek, palate and gums being spectrally similar whereas cells from the tongue and from
the floor of the mouth were spectrally distinct due to an abundance of keratin and collagen respectively.
It was further shown that samples from patients with reactive atypical changes or malignancy associated
changes were more spectrally similar to a sample from a patient with squamous cell carcinoma than to
samples from healthy volunteers [47]. A further IR study from the same group [5,48] showed that
spectra from squamous cells collected from the tongues of healthy volunteers could be discriminated
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from squamous cells collected from the tongues of patients with oral disease, mostly dysplastic and
cancer cases, using unsupervised principal components analysis. An artificial neural network was
trained to automatically distinguish the clinical cases from the normal cases and sensitivity and
specificity values of 96% and 94.3% were obtained. Interestingly, these results were obtained from
morphologically normal cells, the majority of cells present in exfoliated cell samples. This indicates
that biochemical changes can be detected by IR spectroscopy before morphological changes are apparent.
5. Future Perspectives
Vibrational spectroscopy shows great potential as a label free, high sensitivity and specificity test for
cervical and oral cancer screening. The respective techniques of Raman and IR spectroscopy each has
its own potential advantages for clinical applications (reviewed in [49]), with Raman spectroscopy
having a higher spatial resolution, minimal sample preparation, and minimal interference from water and
FTIR spectroscopy having a higher signal to noise ratio allowing faster acquisition times. ATR-FTIR
spectroscopy can achieve higher spatial resolution and can allow measurement from aqueous samples.
Recent advances in these techniques have included surface enhanced Raman spectroscopy (SERS),
which allows significant enhancement of the Raman signal through close proximity/adsorption onto
a roughened metal surface, a colloidal solution or a roughened electrode, tip enhanced Raman spectroscopy
(TERS) which combines the high spatial resolution of atomic force microscopy with SERS, coherent
anti-Stokes Raman scattering (CARS) and stimulated Raman scattering (SRS) (reviewed in [50])
which allow rapid real time imaging of single cells, and the development of high brightness quantum
cascade lasers to improve acquisition times for IR imaging. For cytology applications, a key consideration
is that these spectroscopic techniques could fit into the current workflow. Both Raman and IR
spectroscopy can be operated in microscopic mode and, with automated spectral acquisition, these
techniques could be similar to the Thinprep Imager (Hologic) or the Focal Point GS Imaging system
(BD), which use image processing algorithms to automatically review liquid based cytology Thinprep
and SurePath slides. Both Raman and IR spectroscopy are reagent free, so costs should be favourable
when compared to the imaging systems or to manual scoring where personnel costs could be reduced.
A recent study [35] has shown that glass ThinPrep slides can be used for Raman spectral recording
whereas spectroscopic substrates, such as MirrIR or calcium fluoride substrates, are used for IR
spectroscopy and although they reduce the presence of confounding contributions of the substrate,
they are considerably more expensive than the glass slides used in the cytology laboratory.
However, much work still remains before these techniques could be translated into standard clinical
practice [51]. Many studies have used relatively small sample sizes and as such may be biased.
Screening populations are heavily weighted towards negative results with only a small percentage of
positive results so validation in large multi centre studies is needed using real world cytology samples
from screening populations. Large scale clinical trials are needed to obtain the large volumes of data
necessary for the development of robust classification algorithms and histopathology rather than
cytology should be used to classify the samples.
If spectroscopy can be shown to be as good as, or better than, the gold standard histopathology,
then there is great potential for these techniques to be used as an alternative or an adjunct to the
current cytology screening methods. The advantages would be higher accuracy, higher throughput
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and reduced workload for the cytologist/pathologist and higher accuracy and chance of earlier
detection for the patient.
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